MannKind Corp Climbs 8.6% (MNKD)

Shares of MannKind Corporation (Nasdaq: MNKD) are trading up 8.6% at $8.35 per share during the Tuesday afternoon trading session.

The FDA is set to make a decision on December 29 regarding use of the company's Afrezza product for the treatment of diabetes.

The day's range for shares of MannKind Corporation has been between $7.76 and $8.45 per share.

The average price target of analysts who cover MannKind Corporation (MNKD) is $9.11 per share.

Volume of 4.2 million shares is already more than double the daily average volume of 1.9 million shares.

MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.

Read more from Benzinga's Company news.